Advanced AI Solutions Deliver Hope for CNS Cancer Treatment
Source: Streetwise Reports  (1/15/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation. More >

Tech Innovator Achieves Breakthrough Multi-Market Success
Source: Streetwise Reports  (1/15/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock. More >

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Source: Streetwise Reports  (1/10/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research. More >

Biotech Advances Breakthrough Cancer Treatment Results
Source: Francois Brisebois  (1/10/25)
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note. More >

Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Source: Jason Kolbert  (1/10/25)
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share. More >

Should You Double Down on This Story Stock?
Source: Chris Temple  (1/7/25)
Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX). More >

AI Company Unlocks Breakthrough Medical Diagnostics Platform
Source: Streetwise Reports  (1/6/25)
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide. More >

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
Source: Streetwise Reports  (1/6/25)
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence. More >

Pharma Innovator Unlocks Multi-Disease Treatment Potential
Source: Jason Kolbert  (1/3/25)
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. More >

Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Source: Sean Lee  (1/3/25)
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. More >

Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Source: Dr. Yi Chen  (1/2/25)
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. More >

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug
Source: Ed Arce  (12/31/24)
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target. More >

Analyst Sees Major Growth for Biopharma With Weight-Loss Drug
Source: Ed Arce  (12/31/24)
Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate. More >

Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy
Source: Streetwise Reports  (12/30/24)
Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact. More >

Maryland Biotech Gains Regulatory Approval
Source: Dr. Boobalan Pachaiyappan  (12/26/24)
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients. More >

Pharma Co. Signs License Agreement With Boston Medical Center
Source: Edward White  (12/24/24)
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note. More >

FDA Expedites Review of Gene Therapy Co.'s Drug
Source: Streetwise Reports  (12/23/24)
Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold. More >

Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?
Source: Clive Maund  (12/20/24)
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors. More >

Medical Equipment Co. Shows Strong Profit Margin
Source: Dr. Douglas Loe  (12/20/24)
Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report. More >

Biopharma Using AI to Find Promising Cancer Drug Candidates
Source: Streetwise Reports  (12/19/24)
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development. More >

New Data Supports BLA Package
Source: Andrew Fein  (12/17/24)
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note. More >

New Quebec Law Affecting Healthcare Co.'s Bottom Line
Source: Douglas Lowe  (12/16/24)
Quebec-based staffing operator Premier Health of America Inc. (PHA:TSX.V) reported soft financial data for the fourth quarter of 2024 as the province's Bill 10 act limiting the use of per diem operations. Find out why this analyst thinks things will improve for the company. More >

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says
Source: Streetwise Reports  (12/10/24)
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company. More >

California Biopharma Shows Promising Phase 1 Data
Source: Jason Kolbert  (12/9/24)
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. More >

FDA Decision on Drug for Bone Marrow Due Early 2025
Source: Dr. Douglas Loe  (12/6/24)
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. More >